Advertisement

Topics

Tricida completes $57.5mm Series D round

14:40 EST 9 Nov 2017 | Elsevier Business Intelligence

Tricida Inc. (developing non-absorbed oral therapies for kidney disease) raised $57.5mm in its Series D round. New investors ...

Original Article: Tricida completes $57.5mm Series D round

NEXT ARTICLE

More From BioPortfolio on "Tricida completes $57.5mm Series D round"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...